Quest diagnostics and broad clinical labs to evaluate whole genome sequencing as first-line genetic test for developmental delay

Aim to demonstrate whole genome sequencing can replace the standard diagnostic cascade, for potentially faster diagnosis and lower costs secaucus, n.j. , april 2, 2024 /prnewswire/ -- quest diagnostics (nyse: dgx), a leader in diagnostic information services, and broad clinical labs, the world expert in whole genome sequencing (wgs), today announced a research collaboration designed to demonstrate the clinical value of wgs as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
DGX Ratings Summary
DGX Quant Ranking